The total return over the past 12 months is -18.95% vs. +16.94% for the S&P 500. So far it's up -8.06% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (18.95%) | +7.37% | +16.86% | +0.51% | (0.85%) | +0.71% |
| Total Return CAGR | (18.95%) | +7.37% | +16.86% | +0.51% | (0.85%) | +0.71% |
| Revenue CAGR | +30.90% | +34.57% | +35.61% | +26.97% | +70.31% | +46.95% |
| Net Income CAGR | N/A | N/A | N/A | +26.79% | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | +10.08% | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | +36.17% | +66.18% | +69.40% | +20.55% | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
ANI Pharmaceuticals, Inc. (ANIP)
| Year | Start price | End price | ANIP Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $78.94 | $72.58 | (8.06%) | +14.51% | (22.57%) |
| 2025 | $55.28 | $78.94 | +42.80% | +17.72% | +25.08% |
| 2024 | $55.14 | $55.28 | +0.25% | +24.89% | (24.64%) |
| 2023 | $40.23 | $55.14 | +37.06% | +26.19% | +10.87% |
| 2022 | $46.08 | $40.23 | (12.70%) | (18.17%) | +5.47% |
| 2021 | $29.04 | $46.08 | +58.68% | +28.74% | +29.94% |
| 2020 | $61.67 | $29.04 | (52.91%) | +18.37% | (71.28%) |
| 2019 | $45.02 | $61.67 | +36.98% | +31.22% | +5.76% |
| 2018 | $64.45 | $45.02 | (30.15%) | (4.56%) | (25.59%) |
| 2017 | $60.62 | $64.45 | +6.32% | +21.70% | (15.38%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
